|
業務類別
|
Biotechnology |
|
業務概覽
|
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells. |
| 公司地址
| 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104 |
| 電話號碼
| +1 267 817-5790 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.centurytx.com |
| 員工數量
| 78 |
| Dr. Gregory Russotti, PhD |
Chief Technology and Manufacturing Officer |
美元 559.65K |
27/04/2026 |
| Mr. Douglas Carr |
Principal Finance Officer and Senior Vice President of Finance |
-- |
27/04/2026 |
| Dr. Brent Pfeiffenberger, M.B.A.,Pharm.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 640.63K |
27/04/2026 |
| Dr. Chad Cowan, PhD |
Chief Scientific Officer |
美元 559.53K |
27/04/2026 |
|
|
| Ms. Daphne E. Quimi |
Independent Director |
27/04/2026 |
| Dr. Martin Patrick Murphy, PhD |
Independent Director |
27/04/2026 |
| Dr. Kimberly L. Blackwell, M.D. |
Independent Director |
27/04/2026 |
| Dr. Alessandro Riva, M.D. |
Independent Director |
27/04/2026 |
| Dr. Brent Pfeiffenberger, M.B.A.,Pharm.D. |
Chairman of the Board, President and Chief Executive Officer |
27/04/2026 |
| Dr. Han Myung Lee |
Independent Director |
27/04/2026 |
|
|
|
|
